Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bluejay DiagnosticsBJDX -7.46%22 EV-to-EBITDA is 0.40 as of Aug. 02, 2026, which is 38% below its 10-year median of 0.65. GuruFocus rates BJDX with a GF Score™ of 22/100. Among 510 Medical Devices & Instruments companies, Bluejay Diagnostics ranks better than 98.04% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Bluejay Diagnostics's enterprise value is $-2.68 Mil.
Bluejay Diagnostics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $-6.75 Mil. Therefore, Bluejay Diagnostics's EV-to-EBITDA for today is 0.40.
The historical rank and industry rank for Bluejay Diagnostics's EV-to-EBITDA or its related term are showing as below:
BJDX'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -4.36 Med: 0.65 Max: 0.66
Current: 0.4
During the past 7 years, the highest EV-to-EBITDA of Bluejay Diagnostics was 0.66. The lowest was -4.36. And the median was 0.65.
BJDX's EV-to-EBITDA is ranked better than 98.04% of 510
companies
in the Medical Devices & Instruments industry
Industry Median: 14.415
vs BJDX: 0.40
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Bluejay Diagnostics's PE Ratio (TTM) for today is calculated as:
Bluejay Diagnostics's share price for today is $0.8761.
Bluejay Diagnostics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-13.995.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Bluejay Diagnostics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Bluejay Diagnostics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bluejay Diagnostics EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bluejay Diagnostics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Bluejay Diagnostics's EV-to-EBITDA falls into.
Bluejay Diagnostics's current Enterprise Value is $-2.68 Mil.
Bluejay Diagnostics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.75 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bluejay Diagnostics (BJDX) has a EV-to-EBITDA of 0.40 as of Aug. 02, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Bluejay Diagnostics. This is 38% below median its historical median of 0.65. According to the industry distribution chart, Bluejay Diagnostics ranks #10 out of 510 companies in the Medical Devices & Instruments industry, placing it in the top 2%.
Is Bluejay Diagnostics' EV-to-EBITDA too high?
Bluejay Diagnostics' current EV-to-EBITDA of 0.40 is 38% below median its 10-year median of 0.65. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.42. Bluejay Diagnostics' value of 0.40 is 97.2% below this industry median. Based on the distribution chart, Bluejay Diagnostics ranks #10 out of 510 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Bluejay Diagnostics has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Bluejay Diagnostics' EV-to-EBITDA compare to VTAK and PFSA?
According to the Medical Devices & Instruments industry distribution chart, Bluejay Diagnostics ranks #10 out of 510 companies for EV-to-EBITDA. This places Bluejay Diagnostics in the top 2% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 14.42. Bluejay Diagnostics' value of 0.40 is 97.2% below this benchmark. While the company's 10-year median is 0.65 vs. the industry median of 14.42, Bluejay Diagnostics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.42, based on 510 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bluejay Diagnostics's current EV-to-EBITDA of 0.40 is 97.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Bluejay Diagnostics. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bluejay Diagnostics's current EV-to-EBITDA is 0.40, which is 38% below median its own 10-year median of 0.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bluejay Diagnostics stock overvalued right now?
Bluejay Diagnostics (BJDX) has a current EV-to-EBITDA of 0.40. The current EV-to-EBITDA is 0.40, which is 38% below median its 10-year median of 0.65 and 97.2% below the Medical Devices & Instruments industry median of 14.42. Bluejay Diagnostics' overall GF Score™ is 22/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Bluejay Diagnostics (BJDX), the current EV-to-EBITDA is 0.40 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bluejay Diagnostics Inc is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a cost-effective, rapid, near-patient testing system for sepsis triage and monitoring of disease progression. Bluejay's first product candidate, an IL-6 Test for sepsis, is designed to provide accurate, reliable results in approximately 20 minutes from sample-to-result to help medical professionals make earlier and quicker triage/treatment decisions.
22GF Score
Get the complete analysis for BJDX
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BJDX has been successfully added to your 
